Skip to main content

I-Mab and Nhwa Announce Novel Alzheimer's Drug Starts US Trials

Shanghai I-Mab announced that the first patient has been dosed in a US Phase I study of Protollin, a novel immune therapy for Alzheimer's disease. Protollin is composed of outer membrane proteins of bacteria complexed with lipopolysaccharides. In preclinical tests, it modulated immune cells and showed potential to treat disorders that have an immune component. It is delivered via a nasal spray to reach the brain. I-Mab and Nhwa Pharma, a Jiangsu CNS company. share global rights to Protollin. More details.... Stock Symbols: (NSDQ: IMAB) (SHZ: 002262) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.